Search

Automated real time quality monitoring is one of the key enablers for future high-speed production. In this research, an in-process monitoring procedure based on computer vision inspection and deep learning is proposed to indicate the tool and part quality during soft tooling injection moulding. Multiple types of injection moulding defects can be detected by the proposed method. Geometrical dimensions of the part can be measured simultaneously and the uncertainty can be quantified. Based on the obtained data, automated quality evaluation can be achieved in-process and a decision signal can be sent back to the injection moulding system for process adjustment. [ABSTRACT FROM AUTHOR]

The fast-growing wearable and portable electronics bring imperative demand for high-performance stretchable electromagnetic interference (EMI) shielding materials to tackle the issue of electromagnetic (EM) wave pollution. In this work, highly stretchable and conductive graphene/polydimethylsiloxane lattices are fabricated through a facile 3D printing technique. Benefiting from the unique 3D interconnected and robust conductive network, the resultant composite lattices deliver excellent stretchability of 130%, tunable EMI shielding effectiveness (SE) as high as 45 dB, along with exceptional durability, showing over 90% retention of EMI SE even after 200 cycles of repeated stretching and releasing at strains up to 100%. In addition, the composite lattices exhibit outstanding shielding stability, because the deformation of lattice structure effectively shares the external strain, and the filaments perpendicular to the loading direction act as stabilizing layers preventing the steep resistance changes. The exceptional combination of mechanical properties and EMI shielding performance of the composite lattice provide a brand new perspective for next-generation flexible and stretchable electronics. Image 1 [ABSTRACT FROM AUTHOR]

• The multi-period active-reactive coordination scheduling strategy considering the operation characteristics and reactive power adjustment ability of adjustable resources is proposed to formulate a reasonable and efficient scheduling plan. Meanwhile, the effectiveness and practicality of the proposed strategy are verified through four typical operating scenarios and three proposed evaluation indicators. • An efficient solution method for active-reactive coordinated scheduling model is proposed based on the accurate linearization modeling of ESS, CB and OLTC. Then, the MISOCP are further converted into 0–1 MISOCP to solve accurately and efficiently. Finally, the excellent performances of the proposed linear modelling method have been validated by four operating schemes. • The sensitivity for adjustment step and action time of discrete controllable devices are analyzed in depth. Meanwhile, the adjustment step and action time of discrete controllable devices influence on the optimization results is discussed in detail. Nowadays, the active distribution network (ADN) is facing great challenges on safe operation and coordinated scheduling. To resolve these issues, a novel multi-period active-reactive coordination scheduling strategy efficient solution method is proposed in this paper after addressing the uncertainty of DG and load by probabilistic scenario method. Firstly, based on the second-order cone relaxation (SOCR), the power flow equations are convexized and relaxed to transform the original model into mixed integer second-order cone programming (MISOCP). Then, the controllable resources such as on-load tap changer (OLTC), capacitor banks (CB) and ESS are accurately linearized, so the model is converted to 0–1 MISOCP problem. Finally, compared with the existing strategies, numerical tests on the modified IEEE 33-bus test system demonstrate that on the premise of realizing the maximum utilization of DG, the proposed strategy can also achieve the purposes of energy-saving, loss reduction and improvement in voltage level and the utilization of ESS. Meanwhile, the accuracy and efficiency of the 0–1 MISOCP model are verified through four operating schemes. In addition, the sensitivity analysis of adjustment step and action time of the discrete adjustment devices on optimization results is carried out in detail. [ABSTRACT FROM AUTHOR]

Within the field of medical science, there is a great deal of interest in investigating cell death pathways in the hopes of discovering new drugs. Over the past two decades, pharmacological research has focused on necroptosis, a cell death process that has just been discovered. Receptor-interacting protein kinase 1 (RIPK1), an essential regulator in the cell death receptor signalling pathway, has been shown to be involved in the regulation of important events, including necrosis, inflammation, and apoptosis. Therefore, researching necroptosis inhibitors offers novel ways to treat a variety of disorders that are not well-treated by the therapeutic medications now on the market. The research and medicinal potential of RIPK1 inhibitors, a promising class of drugs, are thoroughly examined in this study. The journey from the discovery of Necrostatin-1 (Nec-1) to the recent advancements in RIPK1 inhibitors is marked by significant progress, highlighting the integration of traditional medicinal chemistry approaches with modern technologies like high-throughput screening and DNA-encoded library technology. This review presents a thorough exploration of the development and therapeutic potential of RIPK1 inhibitors, a promising class of compounds. Simultaneously, this review highlights the complex roles of RIPK1 in various pathological conditions and discusses potential inhibitors discovered through diverse pathways, emphasizing their efficacy against multiple disease models, providing significant guidance for the expansion of knowledge about RIPK1 and its inhibitors to develop more selective, potent, and safe therapeutic agents. [Display omitted] • Necroptosis indispensably regulates various cell death pathways. • Inhibition of RIPK1 is crucial for some severe diseases. • Overview of the latest research advancements in RIPK1 inhibitors. • Guiding for in-depth drug discovery of RIPK1 inhibitors. [ABSTRACT FROM AUTHOR]